HORTENSE BISSILA: Open Payments
NPI 1538627781 · GLENDALE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,882 in 79 payments from 9 companies in 2025. Trend: 2023 $869 · 2024 $1,302 · 2025 $1,882
Food & beverage: $1,882
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 38 | $511 |
| Alkermes, Inc. | 12 | $486 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $208 |
| Janssen Pharmaceuticals, Inc | 6 | $194 |
| Teva Pharmaceuticals USA, Inc. | 8 | $154 |
| Axsome Therapeutics, Inc. | 1 | $122 |
| Otsuka America Pharmaceutical, Inc. | 4 | $94 |
| Neurocrine BioSciences, Inc. | 3 | $67 |
| Tris Pharma Inc | 2 | $45 |
Products named: COBENFY, ARISTADA, LYBALVI, CAPLYTA, INVEGA SUSTENNA, Auvelity, UZEDY, INGREZZA.
Industry payments across AZ — which companies pay providers there.
